Company intelligence / Profile preview
Hebei Phoenix Biotechnology
Not specified; likely Shijiazhuang based on regional business activity but not confirmed., Hebei Sheng (Province), Chinapryzm.ozmosi.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Hebei Phoenix Biotechnology is a private Chinese biotech company focused on immune system diseases, particularly rheumatoid arthritis. Its lead asset, FNS-007, is a small molecule HLA blocker that completed a Phase 1 clinical trial for rheumatoid arthritis in China in February 2023. No additional clinical results or late-stage assets are publicly reported.
- Therapeutic areas
- Immunology
- Modalities
- Small molecule drugSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hebei Phoenix Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hebei Phoenix Biotechnology.